El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
La EMA recomienda no aprobar el fármaco de Puma Biotech
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Puma – PHARMA
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma – PHARMA
Puma Biotechnology
Puma Biotechnology Surging
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma – PHARMA
Puma Men – PHARMA
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
PharmaBg
PHARMA JONPI .: 08/24/14
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
